



The Medical Journal of Australia

Appendix 1

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: Chalasani S, Peiris DP, Usherwood T, et al. Reducing cardiovascular disease risk in diabetes: a randomised controlled trial of a quality improvement initiative. *Med J Aust* 2017; 206: 446-441. doi: 10.5694/mja16.00332.

Appendix 1: Guidelines reviewed for development of the HealthTracker algorithm

| Professional Organisation | Guideline |
|--|--|
| National Vascular Disease Prevention Alliance | Guidelines for the Assessment of Absolute Cardiovascular Disease Risk 2009 |
| Royal Australian College of General Practitioners | Guidelines for preventive activities in general practice 2009 |
| Kidney Health Australia | Chronic Kidney Disease Management (CKD) in General Practice 2007 |
| Royal Australian College of General Practitioners /Diabetes Australia | Diabetes Management in General Practice 2010/2011 |
| Diabetes Australia Consortium | NHMRC Evidence Based Guidelines for Case Detection and Diagnosis of Type 2 Diabetes 2009 |
| | NHMRC Evidence Based Guidelines for Diagnosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes 2009 |
| National Heart Foundation | Reducing Risk in Heart Disease 2008 |
| | Guide to Management of Hypertension 2008 – Updated Aug 2009 |
| | Aspirin for cardiovascular disease prevention 2003 |
| National Heart Foundation/Cardiac Society of Australia and New Zealand | The Lipid Position Statement 2005 |
| National Stroke Foundation | Clinical Guidelines for Stroke Management 2010 |
| Department of Health and Aging | Schedule of Pharmaceutical Benefits Scheme 2011 General Statement for Lipid Lowering Drugs |